Guanine derivatives as promising candidates for the development of purine-based antimalarial drugs

Worlanyo Tashie¹Harry P. De Koning²Nancy Odurowah Duah-Quashie^1,3Neils Benjamin Quashie^1,3,4*

• ¹West African Centre for C ell Biology of Infectious Pathogens, University of Ghana, Accra, Ghana, Accra, Ghana
• ²University of Glasgow, Glasgow, United Kingdom
• ³University of Ghana Noguchi Memorial Institute for Medical Research, Accra, Ghana
• ⁴University of Ghana, Accra, Ghana

The increasing resistance of Plasmodium falciparum to existing antimalarial drugs drives the urgent need for novel therapeutic strategies. The purine salvage pathway in P. falciparum is essential for the parasite's survival due to its complete reliance on host-derived purines for nucleic acid synthesis and other essential processes. Although the purine salvage system has been intensively researched, no purine-based antimalarial drugs have been taken into preclinical development. The current study evaluated the chemotherapeutic potential of some purine nucleobase analogues against P. falciparum. In vitro sensitivity assays were conducted using the 72-hour SYBR Green drug assay on laboratory-adapted P. falciparum strains 3D7 and Dd2. The analogues 8-azaguanine, 7-deazaguanine, and 6-thioguanine exhibited average EC50 values of 1.71 µM, 14.9 µM and 15.7 µM, respectively, for 3D7 and 5.2 µM, 16.3 µM and 18.6 µM, respectively, for the Dd2 strain, and subsequently tested against field isolates of P. falciparum. These ex vivo tests showed EC50 values ranging from 0.5 -4.5 µM for 8-azaguanine, 3.8 -12.3 µM for 7deazaguanine, and 4.1 -15.0 µM for 6-thioguanine. To understand their cellular targeting, molecular docking of the same analogues was performed using the structure of P. falciparum Equilibrative Nucleoside Transporter 1 (PfENT1). This demonstrated that guanine, 8-azaguanine and 7-deazaguanine formed five hydrogen bonds each with the same amino acid residues of PfENT1, whereas 6-thioguanine's orientation allowed only two hydrogen bonds with PfENT1. The binding pose of inosine was different from these nucleobases. These findings highlight the potential of guanine-based scaffolds, particularly 8-azaguanine and 7-deazaguanine, as promising leads for purine-based antimalarial drug development and the versatility of the PfENT1 transporter in the uptake of purine antimetabolites.